Obesity trials recruiting in Michigan

All Obesity trials nationally

Cities in Michigan

Recruiting trials in Michigan

• A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
  NCT06143956 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Michigan: Southfield, Troy
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
  NCT07667803 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Ypsilanti
• A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
  NCT06672549 · Phase: Phase 3 · Ages: 6 Years to 17 Years · Sex: All (male and female) · Michigan: Grand Rapids
• A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
  NCT06717698 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Flint
• A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
  NCT07564414 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Buckley
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
  NCT07567001 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Bloomfield Hills, Grand Rapids, Lansing, Southfield
• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
  NCT07321886 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Troy
• A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
  NCT07369011 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Southfield
• A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
  NCT07392190 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Southfield, Troy
• A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
  NCT07743450 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Southfield
• A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight
  NCT07202884 · Phase: Phase 3 · Ages: 18 Years and older · Sex: Female · Michigan: Troy
• A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
  NCT07784725 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Troy
• A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
  NCT06864026 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Saint Clair Shores
• A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
  NCT07589608 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Michigan: Southfield, Troy
• A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
  NCT06857942 · Phase: Phase 4 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Ann Arbor, Caledonia
• A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
  NCT07595549 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Flint
• A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight
  NCT07662122 · Phase: Phase 2 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Michigan: Troy
• AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
  NCT07509307 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Troy
• Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
  NCT05082519 · Phase: Phase 2 · Ages: 7 Years to 25 Years · Sex: All (male and female) · Michigan: Ann Arbor
• Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
  NCT07654361 · Phase: Phase 3 · Ages: 18 Years to 79 Years · Sex: All (male and female) · Michigan: Ann Arbor
• Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity
  NCT07497880 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Michigan: Garden City
• Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
  NCT07284979 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Farmington Hills
• Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
  NCT07284901 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Farmington Hills
• Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
  NCT07575399 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Michigan: Troy
• Exercise Effects on Adipose Tissue Structure and Function
  NCT04812314 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 40 Years · Sex: All (male and female) · Michigan: Ann Arbor
• Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
  NCT07684235 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Michigan: Southfield
• Families in Balance: Enhancing Household Routines and Reducing Early Childhood Obesity Among Families With Low-income
  NCT06795490 · Phase: Not applicable (e.g. observational or device study) · Ages: 2 Years and older · Sex: All (male and female) · Michigan: Ann Arbor
• Food-Body-Mind Intervention (16 Weeks)
  NCT06597474 · Phase: Phase 2, Phase 3 · Ages: 3 Years to 5 Years · Sex: All (male and female) · Michigan: Jackson
• Identification of Phenotypic Factors That Predict Success for Weight Loss and Long-term Weight Maintenance
  NCT02043457 · Phase: Not specified · Ages: 15 Years to 75 Years · Sex: All (male and female) · Michigan: Ann Arbor
• Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
  NCT07037459 · Phase: Phase 3 · Ages: 18 Years to 99 Years · Sex: All (male and female) · Michigan: Ann Arbor, Bloomfield Township, Detroit, Grand Rapids
• Metabolic Adaptations to Weight Loss With and Without Exercise
  NCT05806801 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 40 Years · Sex: All (male and female) · Michigan: Ann Arbor
• Michigan Weight Navigation Program (MiWeigh) Study
  NCT07465341 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · Michigan: Ann Arbor
• Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss
  NCT04228978 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Michigan: Detroit
• RESET System Pivotal Trial (Rev F)
  NCT04101669 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years to 65 Years · Sex: All (male and female) · Michigan: Ann Arbor
• The Bottle Optimization Testing Tiny Little Eaters Study
  NCT07665983 · Phase: Not applicable (e.g. observational or device study) · Ages: 4 Months and older · Sex: All (male and female) · Michigan: Ann Arbor
• Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
  NCT06007404 · Phase: Not specified · Ages: 14 Years to 18 Years · Sex: All (male and female) · Michigan: Ann Arbor